ABSTRACT
Background Understanding SARS-CoV-2 infection in children is necessary to reopen schools safely.
Methods We measured SARS-CoV-2 infection in 320 learners [10.5 ± 2.1(sd); 7-17 y.o.] at four diverse schools with either remote or on-site learning. Schools A and B served low-income Hispanic learners; school C served many special-needs learners; and all provided predominantly remote instruction. School D served middle- and upper-income learners, with predominantly on-site instruction. Testing occurred in the fall (2020), and 6-8 weeks later during the fall-winter surge (notable for a tenfold increase in COVID-19 cases). Immune responses and mitigation fidelity were also measured.
Results We found SARS-CoV-2 infections in 17 learners only during the surge. School A (97% remote learners) had the highest infection (10/70, 14.3%, p<0.01) and IgG positivity rates (13/66, 19.7%). School D (93% on-site learners) had the lowest infection and IgG positivity rates (1/63, 1.6%). Mitigation compliance [physical distancing (mean 87.4%) and face covering (91.3%)] was remarkably high at all schools. Documented SARS-CoV-2-infected learners had neutralizing antibodies (94.7%), robust IFN-γ+ T cell responses, and reduced monocytes.
Conclusion Schools can implement successful mitigation strategies across a wide range of student diversity. Despite asymptomatic to mild SARS-CoV-2 infection, children generate robust humoral and cellular immune responses.
Key Points
Successful COVID-19 mitigation was implemented across a diverse range of schools.
School-associated SARS-CoV-2 infections reflect regional rates rather than remote or on-site learning.
Seropositive school-aged children with asymptomatic to mild SARS-CoV-2 infections generate robust humoral and cellular immunity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NIH NCATS UCI Clinical and Translational Science Award UL1 TR001414; R01AI142841; R21AI143301; Orange County Health Care Agency Research Fund; UCI COVID-19 Research Fund; Support was provided in part by the Robert Wood Johnson Foundation and the National Institute of Allergy and Infectious Diseases, NIH (K08 AI151253-01) to ERU.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the institutional review boards at the Childrens Hospital of Orange County and the University of California Irvine
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest Disclosure: The authors have no conflict of interest to disclose.
Category of Study: Population cohort observational
Consent: Consent and assent were required and obtained
Funding/Support: NIH NCATS UCI Clinical and Translational Science Award UL1 TR001414; R01AI142841; R21AI143301; Orange County Health Care Agency Research Fund; UCI COVID-19 Research Fund; Support was provided in part by the Robert Wood Johnson Foundation and the National Institute of Allergy and Infectious Diseases, NIH (K08 AI151253-01) to ERU.
Data Availability
The data that support the findings of this study are openly available in medRxiv.
Abbreviations
- CHOC
- Children’s Hospital of Orange County
- OCHCA
- Orange County Health Care Agency
- SOCOM
- Systematic Observation of COVID-19 Mitigation
- HDL
- high-density lipoprotein
- LDL
- low-density lipoprotein
- PBMCs
- peripheral blood mononuclear cells
- NP
- nucleocapsid protein
- RBD
- receptor binding domain
- NK
- natural killer cells
- mDCs
- myeloid dendritic cells
- PD-1
- programmed death cell protein 1
- MFI
- mean fluorescence intensity
